

Table 35.4
 Comparison of 5-Year Relative Survival^a(Percent) using different Expected Rate Tables
 By Primary Cancer Site and Stage at Diagnosis
 White Males, 2008-2014

Site	Stage at Diagnosis						Unstaged/Unknown USLT ^b SES ^c	
	Localized USLT ^b SES ^c		Regional USLT ^b SES ^c		Distant USLT ^b SES ^c			
All Sites	90.5	90.4	62.0	62.0	26.8	26.7	36.0	35.8
Oral Cavity & Pharynx	82.9	83.0	68.1	68.0	40.4	40.4	46.4	46.4
Esophagus	50.0	50.1	23.7	23.7	4.6	4.6	12.0	12.0
Stomach	63.5	63.3	28.9	28.8	5.5	5.4	18.5	18.3
Colon & Rectum	89.1	89.2	71.8	71.8	13.4	13.4	35.2	35.1
Liver & Intrahepatic Bile Duct	30.0	29.9	10.4	10.4	2.2	2.1	5.3	5.2
Pancreas	37.1	37.0	12.4	12.4	2.7	2.7	6.0	6.0
Larynx	78.3	78.5	45.4	45.4	33.8	33.8	57.3	57.2
Lung & Bronchus	50.2	50.5	26.1	26.2	3.7	3.7	6.4	6.4
Melanoma of the Skin	97.4	97.3	61.3	61.3	21.1	21.1	80.1	80.3
Prostate	100.0	100.0	100.0	99.8	32.9	32.7	88.4	88.0
Urinary Bladder	71.7	71.7	37.2	37.2	4.9	4.8	48.1	48.0
Kidney & Renal Pelvis	92.6	92.5	70.4	70.4	11.8	11.8	37.0	37.0
Hodgkin Lymphoma	92.9	92.8	92.5	92.4	79.3	79.2	78.7	78.6
Non-Hodgkin Lymphoma	82.8	82.7	75.4	75.3	63.3	63.2	64.7	64.5
Myeloma	74.0	73.8	-	-	48.7	48.6	-	-
Leukemia	49.5	49.5	-	-	62.7	62.7	-	-
Acute Lymphocytic Leuk	-	-	-	-	67.6	67.5	-	-

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Based on follow-up of patients into 2015

^c Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: <https://seer.cancer.gov/expsurvival/>.

Table 35.4 cont.
 Comparison of 5-Year Relative Survival^a(Percent) using different Expected Rate Tables
 By Primary Cancer Site and Stage at Diagnosis
 White Females, 2008-2014

Site	Stage at Diagnosis							
	Localized		Regional		Distant		Unstaged/Unknown	
	USLT ^b	SES ^c	USLT ^b	SES ^c	USLT ^b	SES ^c	USLT ^b	SES ^c
All Sites	91.6	91.4	69.4	69.3	26.7	26.7	28.4	28.3
Oral Cavity & Pharynx	84.7	84.5	61.7	61.7	38.0	38.0	48.6	48.5
Esophagus	37.4	37.4	26.2	26.2	7.3	7.3	10.9	10.8
Stomach	72.0	71.4	30.2	29.9	4.2	4.2	27.2	26.9
Colon & Rectum	91.1	90.9	71.9	71.7	15.4	15.4	29.0	28.8
Liver & Intrahepatic Bile Duct	30.8	30.6	11.9	11.9	4.0	3.9	6.0	5.9
Pancreas	31.8	31.7	10.6	10.6	2.6	2.6	3.8	3.7
Larynx	75.0	75.2	48.1	48.2	33.9	33.9	53.0	52.8
Lung & Bronchus	61.3	61.3	33.2	33.3	5.5	5.5	7.6	7.6
Melanoma of the Skin	98.9	98.8	68.2	68.1	24.7	24.7	85.1	85.1
Breast	99.7	99.6	85.9	85.8	25.2	25.2	47.9	47.6
Cervix	87.7	87.4	51.9	51.7	16.7	16.6	33.1	32.9
Corpus & Uterus, NOS	95.8	95.7	70.1	69.9	15.7	15.6	43.9	43.8
Ovary	87.2	87.3	60.2	60.2	21.3	21.3	10.8	10.8
Urinary Bladder	63.3	63.1	31.4	31.3	4.5	4.4	34.2	34.1
Kidney & Renal Pelvis	93.3	93.3	66.8	66.7	11.7	11.6	34.1	33.9
Hodgkin Lymphoma	91.3	91.3	94.5	94.4	77.2	77.0	85.6	85.4
Non-Hodgkin Lymphoma	84.3	84.2	75.8	75.7	67.4	67.3	70.8	70.4
Myeloma	70.6	70.6	-	-	48.9	48.8	-	-
Leukemia	48.8	48.9	-	-	60.7	60.7	-	-
Acute Lymphocytic Leuk	-	-	-	-	69.1	69.1	-	-

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Based on follow-up of patients into 2015

^c Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: <https://seer.cancer.gov/expsurvival/>.

Table 35.4 cont.
 Comparison of 5-Year Relative Survival^a(Percent) using different Expected Rate Tables
 By Primary Cancer Site and Stage at Diagnosis
 Black Males, 2008-2014

Site	Stage at Diagnosis						Unstaged/Unknown USLT ^b SES ^c	
	Localized USLT ^b SES ^c		Regional USLT ^b SES ^c		Distant USLT ^b SES ^c			
All Sites	91.0	90.9	56.5	56.4	21.9	21.8	33.5	33.3
Oral Cavity & Pharynx	75.7	75.7	48.0	48.0	28.9	28.9	44.9	44.9
Esophagus	26.0	26.1	17.3	17.3	1.9	1.9	10.3	10.3
Stomach	58.3	58.2	31.1	31.1	4.9	4.9	13.9	13.8
Colon & Rectum	85.0	84.8	62.7	62.6	9.5	9.5	39.1	38.9
Liver & Intrahepatic Bile Duct	24.5	24.4	7.1	7.1	1.1	1.1	8.9	8.9
Pancreas	26.0	25.9	12.8	12.8	2.4	2.4	9.2	9.2
Larynx	72.6	72.6	39.2	39.3	31.0	31.1	30.9	30.8
Lung & Bronchus	44.7	44.6	23.7	23.7	3.9	3.9	8.4	8.3
Melanoma of the Skin	87.5	87.2	36.5	36.4	13.4	13.5	-	-
Prostate	100.0	100.0	100.0	100.0	33.3	33.3	85.1	84.8
Urinary Bladder	63.4	63.0	23.8	23.7	4.6	4.6	48.6	48.2
Kidney & Renal Pelvis	91.8	91.8	61.4	61.4	7.4	7.4	51.6	51.5
Hodgkin Lymphoma	92.0	92.2	91.2	91.4	71.4	71.4	73.2	73.1
Non-Hodgkin Lymphoma	76.0	76.0	71.8	71.8	55.4	55.3	60.8	60.7
Myeloma	70.4	70.4	-	-	50.6	50.4	-	-
Leukemia	-	-	-	-	56.9	56.9	-	-
Acute Lymphocytic Leuk	-	-	-	-	66.0	66.0	-	-

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Based on follow-up of patients into 2015

^c Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: <https://seer.cancer.gov/expsurvival/>.

Table 35.4 cont.
 Comparison of 5-Year Relative Survival^a(Percent) using different Expected Rate Tables
 By Primary Cancer Site and Stage at Diagnosis
 Black Females, 2008-2014

Site	Stage at Diagnosis						Unstaged/Unknown USLT ^b SES ^c	
	Localized USLT ^b SES ^c		Regional USLT ^b SES ^c		Distant USLT ^b SES ^c			
All Sites	86.9	87.0	61.0	61.1	22.5	22.5	28.5	28.5
Oral Cavity & Pharynx	84.0	84.1	46.7	46.8	29.3	29.3	33.4	33.3
Esophagus	25.6	25.7	20.9	20.9	7.3	7.4	12.3	12.3
Stomach	72.9	72.7	31.0	30.9	8.4	8.4	27.2	27.1
Colon & Rectum	87.9	87.9	67.5	67.6	11.3	11.3	36.8	36.6
Liver & Intrahepatic Bile Duct	30.0	30.0	8.9	8.9	0.0	0.0	6.7	6.7
Pancreas	34.1	34.1	11.4	11.4	3.4	3.4	8.5	8.5
Larynx	65.3	65.4	48.7	48.9	31.5	31.6	-	-
Lung & Bronchus	59.0	59.1	31.0	31.1	5.6	5.6	12.8	12.7
Melanoma of the Skin	84.3	84.3	55.8	56.0	39.8	39.8	-	-
Breast	95.8	95.9	75.9	76.0	17.0	17.0	43.9	43.5
Cervix	82.5	82.7	46.6	46.6	11.2	11.2	27.3	27.2
Corpus & Uterus, NOS	84.0	84.1	45.9	46.0	7.8	7.8	36.6	36.5
Ovary	72.2	72.1	41.2	41.1	13.3	13.4	9.4	9.3
Urinary Bladder	49.8	49.6	31.6	31.7	1.4	1.4	19.0	19.0
Kidney & Renal Pelvis	89.9	90.1	63.4	63.6	13.1	13.2	38.3	38.2
Hodgkin Lymphoma	91.8	91.8	92.8	92.9	83.0	83.1	-	-
Non-Hodgkin Lymphoma	84.1	84.1	69.2	69.2	60.5	60.6	67.0	66.9
Myeloma	60.7	60.8	-	-	52.6	52.6	-	-
Leukemia	-	-	-	-	53.6	53.6	-	-
Acute Lymphocytic Leuk	-	-	-	-	60.2	60.2	-	-

^a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^b Based on follow-up of patients into 2015

^c Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: <https://seer.cancer.gov/expsurvival/>.